Henry Meds vs Ivim Health: Programs, Pricing, Genetics

This guide is published in the PlexusDx Education Hub, our library of evidence-first reading on GLP-1 therapy, weight management protocols, and the inherited biology behind every metabolic result. Browse all Peptides & GLP-1 education

What follows is independent editorial analysis. PlexusDx holds no commercial relationship with Henry Meds or Ivim Health, runs no affiliate links, and receives no compensation for either mention.

Full head-to-head: PlexusDx vs Henry Meds →

Shoppers who type "Henry Meds vs Ivim Health" are usually weighing two compounding-pharmacy telehealth programs against each other. This piece lines them up on structure, medication routing, and cost, then adds the one variable neither company puts on the intake form: your genes. As of April 2026 the GLP-1 telehealth field is crowded; here we stay on the two brands in the query.

Ivim Health at a glance

Ivim Health runs on a telehealth-plus-compounded-pharmacy model. A licensed provider reviews your virtual intake and, when appropriate, issues a prescription that a compounding pharmacy fills. Program specifics, medication menus, and rates shift over time, so treat Ivim Health's official website as the authoritative source on the day you read this.

Henry Meds at a glance

Henry Meds also combines virtual evaluation with compounded dispensing. A provider issues the prescription after intake, and Henry can route either brand-name FDA-approved GLP-1 products or compounded semaglutide and tirzepatide through licensed compounding pathways. Current program details live on Henry Meds's official website.

How Henry's subscription actually prices out

Henry bills per medication and leads with a headline figure that only applies if you prepay a full year, so its month-to-month cost sits higher. The ladder below is labeled by plan so you can see which rate is which (verified July 20, 2026):

• Injectable compounded semaglutide, the flagship: $297/month month-to-month. Prepaying cuts it — the 6-month plan works out to $1,482 ($247/month) and the 12-month plan to $2,364 ($197/month). That advertised “$197/month” is the prepaid-in-full annual rate, not a monthly one.
• Oral (sublingual) semaglutide: $249/month month-to-month, with a $179/month tier.
• Oral tirzepatide: dissolving tablets only; Henry lists no injectable tirzepatide as of July 2026. It ships as a 3-month supply at $1,047 ($891 paid in full), with no month-to-month tirzepatide price published.
• Liraglutide (injectable): $179/month month-to-month.
• Phentermine (oral): $149/month.

Henry adds no membership charge and no visit fee — the evaluation is free and nothing bills until a prescription is written, with medication, supplies, shipping, and follow-up bundled into the subscription. Its refund terms are unstated. Ivim posts its own numbers, so rather than repeat a figure that may be stale, confirm Ivim's current rates on its site before deciding. Re-verify Henry's ladder on Henry Meds's official website.

Why the compound, not the brand, drives results

Both companies prescribe within the same pharmacology. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite signaling, satiety, and gastric emptying. That mechanism is identical whether Henry or Ivim writes the script; the differences are business model, brand-versus-compounded routing, oversight, and price. The evidence base sits with the molecules: STEP studied semaglutide for weight management (NEJM 2021), SURMOUNT studied tirzepatide (NEJM 2022), and SURMOUNT-OSA extended tirzepatide to obstructive sleep apnea (NEJM 2024). Effect sizes shift by compound, dose, and population.

The genetic layer neither program maps

What no telehealth intake captures is the inherited terrain a GLP-1 drug lands on. GLP1R encodes the receptor every GLP-1 compound targets; FTO shapes fat-mass and obesity risk; MC4R governs satiety and energy balance; and TCF7L2 influences glucose handling and GLP-1 secretion. These variants are pathway-level context, not a response prediction — they describe the biology a clinician is prescribing into. That is why PlexusDx pairs its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with the Precision Peptide Genetic Test, which reads 14 pathways, 49 peptides, 150+ genetic insights spanning FTO, MC4R, and TCF7L2. It is the test before you invest idea: understand your baseline biology, then have an informed conversation with your provider.

Not affiliated: PlexusDx has no affiliation with Henry Meds or Ivim Health and no commercial tie to any company named here.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Disclaimer: This article is educational. PlexusDx is not affiliated with Henry Meds or Ivim Health and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

See the PlexusDx approach in one place: the Weight Management Protocols pair semaglutide and tirzepatide with genetic context, or begin upstream with the Precision Peptide Genetic Test.

Frequently Asked Questions

Does Henry Meds or Ivim Health cost less?

It depends on medication and commitment length. Henry's injectable compounded semaglutide is $297 month-to-month, dropping to $247 or $197 on prepaid plans. Ivim publishes its own rates separately. Compare each brand's current pricing page directly, since totals shift with product choice and plan term.

Do Henry Meds and Ivim Health use compounded or brand-name GLP-1?

Both can route either FDA-approved brand products or compounded semaglutide and tirzepatide through licensed compounding pharmacies, depending on eligibility and availability. The dispensing pathway, not the platform, determines whether you receive a branded or compounded formulation. Confirm which route applies during each program's intake.

Does the Precision Peptide Genetic Test say which program to pick?

No. It does not predict response to Henry Meds, Ivim Health, or any compound. It maps pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline GLP-1 and appetite biology — upstream context that stays relevant no matter which telehealth service you choose.

Where does PlexusDx fit alongside these two?

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols and adds the Precision Peptide Genetic Test for genetic context. The distinguishing feature is pathway-level insight into FTO, MC4R variants, which Henry Meds and Ivim Health do not offer beside the medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education